<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812483</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00044; ks19Schifferli</org_study_id>
    <nct_id>NCT04812483</nct_id>
  </id_info>
  <brief_title>Immunomodulation With Eltrombopag in ITP</brief_title>
  <acronym>iROM2</acronym>
  <official_title>Immunomodulation in Young Adults With Newly Diagnosed Primary Immune Thrombocytopenia (ITP): A Randomized Open Label Trial With High-dose Dexamethasone Versus Eltrombopag and High-dose Dexamethasone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children's Hospital Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiftung zur Förderung medizinischer und biologischer Forschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg, Department of Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Children's Hospital Basel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate immunomodulatory effects of eltrombopag combined with&#xD;
      dexamethasone in young adult patients with newly diagnosed primary Immune thrombocytopenia&#xD;
      (ITP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to investigate immunomodulatory effects of eltrombopag combined with&#xD;
      dexamethasone in young adult patients with newly diagnosed primary ITP.&#xD;
&#xD;
        1. Intervention phase:&#xD;
&#xD;
           Medical history and physical examination including assessment of severe bleeding every&#xD;
           week until week 4, every second week until week 20. Complete blood count every week&#xD;
           until week 10. For the adjustment of the Thrombopoietin receptor agonist (TPO-RA) dose -&#xD;
           every second week until week 20. Immunologic panel at the beginning and at week 3 and&#xD;
           20.&#xD;
&#xD;
        2. Follow-up:&#xD;
&#xD;
      Three clinical visits are scheduled in the follow-up including a complete blood count: at&#xD;
      week 22, 24 and 30. Immunologic panel will be done at week 30 (end of study).&#xD;
&#xD;
      High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed&#xD;
      by Arm 1 or 2 (1:1 randomization) Arm 1: Standard Arm No planed further treatment. = standard&#xD;
      therapy In case of non-response after 2 courses of HD-DXM (week 4): drop out and alternative&#xD;
      therapy of ITP In case of relapse: repeat HD-DXM (40 mg day 1-4), up to maximal of 6 courses.&#xD;
      Time between 2 courses should be minimal 14 days. Arm 2: Study Arm Eltrombopag (Revolade®),&#xD;
      50 mg per os, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second&#xD;
      day. In case of non-response at week 4: drop out&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized study evaluating the immunomodulatory effects of eltrombopag versus standard high-dose (HD) DXM therapy (1:1) in newly diagnosed ITP.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The laboratory team will be kept blinded regarding information about response or non-response of patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percentual T-regulatory cells (Tregs)</measure>
    <time_frame>before (Tregs/CD4), at week 3 and at the end of the treatment (week 20)</time_frame>
    <description>Assessment of the percentage of Tregs (Tregs/CD4) in the study arm compared to the standard arm. The Tregs will be defined as CD4+CD25+ CD127+ in the fluorescence-activated cell sorting (FACS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Th1/Th2 balance</measure>
    <time_frame>at baseline and weeks 3, 20 and 30</time_frame>
    <description>Change in Th1/Th2 balance will be performed by analysis of immunologic profile (immune cell characteristics, messenger ribonucleic acid (mRNA) of immune cells, cytokines, cytokine concentrations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to eltrombopag therapy</measure>
    <time_frame>trial duration (baseline to week 30)</time_frame>
    <description>Clinical response to eltrombopag therapy (by assessing need of inpatient daycare and use of rescue treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet response to eltrombopag</measure>
    <time_frame>at baseline and weeks 6, 20 and 30</time_frame>
    <description>Platelet response to eltrombopag: proportion of subjects achieving a platelet count of ≥50x109/l (complete response, response and no response;Response at each assessment is defined as a platelet count of ≥ 50x109/l).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>trial duration (baseline to week 30)</time_frame>
    <description>Safety of eltrombopag analyzed by documentation of number of Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe bleeding</measure>
    <time_frame>trial duration (baseline to week 30)</time_frame>
    <description>Severe bleeding is defined as bleeding requiring hospital admission and/or blood transfusion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Primary Immune Thrombocytopenia (ITP)</condition>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:&#xD;
No planed further treatment. = standard therapy (without eltrombopag)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:&#xD;
The subjects in the experimental arm will be treated with eltrombopag:&#xD;
Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag (Revolade®)</intervention_name>
    <description>Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard therapy (without eltrombopag): HD-DXM</intervention_name>
    <description>standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4</description>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent as documented by signature&#xD;
&#xD;
          -  Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a&#xD;
             risk of platelet count of &lt;30x109/l or risk of severe bleeding&#xD;
&#xD;
          -  No previous treatment for ITP&#xD;
&#xD;
          -  No steroids in the last 4 weeks (for other conditions)&#xD;
&#xD;
          -  Bleeding severity and quality of life are neither an inclusion nor an exclusion&#xD;
             criterion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated for ITP (e.g. Steroid, intravenous immunoglobulin (IVIG),&#xD;
             platelet infusion)&#xD;
&#xD;
          -  Life-threatening bleeding (and inability to sign informed consent)&#xD;
&#xD;
          -  Secondary ITP&#xD;
&#xD;
          -  Positive family history for ITP&#xD;
&#xD;
          -  Presence or history of autoimmune disease as judged by the investigator&#xD;
&#xD;
          -  Hepatosplenomegaly in the clinical examination&#xD;
&#xD;
          -  Relevant hepatic disease as judged by the investigator&#xD;
&#xD;
          -  Presence or history of thromboembolic disease&#xD;
&#xD;
          -  Patients with splenectomy&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study&#xD;
&#xD;
          -  Lack of safe double contraception&#xD;
&#xD;
          -  Any vaccination 2 weeks prior start of the study&#xD;
&#xD;
          -  Immunsuppressive and antiplatelet drugs&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, incompetence to judge&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Schifferli, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel, UKBB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Schifferli, Dr. med.</last_name>
    <phone>+41-61-704-1212</phone>
    <email>Alexandra.Schifferli@ukbb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Kühne, Prof. Dr. med.</last_name>
    <phone>+41-61-704-1212</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarau Cantonal Hospital, Division of Hematology</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Cantoni, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Schifferli, Dr. med.</last_name>
      <phone>+41-61-704-1212</phone>
      <email>Alexandra.Schifferli@ukbb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Kühne, Prof. Dr. med.</last_name>
      <phone>+41-61-704-1212</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Hematology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Holbro, PD. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern, Division of Hematology</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Rovò, PD. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liestal Cantonal Hospital, Division of Hematology</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève Favre, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucerne Cantonal Hospital, Division of Hematology</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Rüfer, Dr. med.</last_name>
      <phone>+41 41 205 51 47</phone>
      <email>axel.ruefer@luks.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eltrombopag</keyword>
  <keyword>thrombopoietin receptor agonist (TPO-RA)</keyword>
  <keyword>ITP in young and midlife adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

